Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(13 sites)
Bulgaria
Medical Center "Galileo" OOD, Pleven First University Multiprofile Hospital for Active Treatment MHAT - Neurology Clinic, Sofia University Multiprofile Hospital for Active Treatment "Alexandrovska" EAD, Clinic of Neurological Diseases, Sofia Germany
Neurologie Berlin, Berlin Universitaetsklinikum Carl Gustav Carus, Dresden Poland
Centrum Medyczne NEUROMED, Bydgoszcz Neuro-Care sp. z o.o. sp. Komandytowa, Katowice NeuroKlinika Prof. Andrzej Bogucki, Lodz EuroMedis Sp. z o.o., Szczecin Centrum Medyczne NeuroProtect, Warsaw Spain
Hospital de la Santa Creu i Sant Pau, Unidad de trastornos del movimiento, Barcelona Hospital General Universitario de Elche, Elche Hospital Universitario Ramon y Cajal, Madrid